Compare HRMY & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | SAM |
|---|---|---|
| Founded | 2017 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2020 | 1996 |
| Metric | HRMY | SAM |
|---|---|---|
| Price | $37.03 | $178.19 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 11 |
| Target Price | $44.11 | ★ $233.70 |
| AVG Volume (30 Days) | ★ 854.1K | 282.6K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 95.45 |
| EPS | ★ 0.55 | N/A |
| Revenue | $868,453,000.00 | ★ $1,964,994,000.00 |
| Revenue This Year | $19.75 | $1.02 |
| Revenue Next Year | $12.88 | $1.31 |
| P/E Ratio | $67.75 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $158.68 |
| 52 Week High | $40.87 | $264.46 |
| Indicator | HRMY | SAM |
|---|---|---|
| Relative Strength Index (RSI) | 68.61 | 47.33 |
| Support Level | $35.05 | $170.14 |
| Resistance Level | $39.12 | $188.80 |
| Average True Range (ATR) | 1.04 | 6.57 |
| MACD | 0.22 | 1.18 |
| Stochastic Oscillator | 93.53 | 37.36 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.